Utilising the impact of COVID-19 on trauma throughput to adapt elective care models for more efficient trauma care

Table 4 Patient demographics, length of stay, comorbidity indices and theatre parameters for 2019

	Phase 0 (n = 664)	Phase 1 (n = 563)	Phase 2 (n = 1315)	Phase 3 (n = 471)	Total (n = 3013)
	mean ± SD
Age at injury	58.89 ± 24.03	60.66 ± 23.17	58.66 ± 23.95	61.11 ± 22.98	59.47 ± 23.68
Length of spell (d)	7.30 ± 8.05	7.50 ± 9.90	6.67 ± 8.60	8.01 ± 10.88	7.18 ± 9.14
Charlson Comorbidity Index	0.71 ± 1.28	0.84 ± 1.49	0.78 ± 1.35	0.77 ± 1.30	0.77 ± 1.35
Elixhauser Comorbidity Index	1.20 ± 1.38	1.36 ± 1.55	1.39 ± 1.53	1.34 ± 1.42	1.33 ± 1.49
Hours to surgery	32.02 ± 57.64	32.13 ± 51.56	29.17 ± 47.03	31.96 ± 56.83	30.79 ± 51.99
Time in theatre	101.03 ± 49.49	96.30 ± 67.04	94.85 ± 57.61	95.95 ± 47.63	96.64 ± 56.36
Time in theatre/recovery	213.08 ± 110.23	208.29 ± 115.17	214.99 ± 141.51	228.39 ± 146.20	215.56 ± 131.70
Sex: Female	332 ± 50.0%	291 ± 51.7%	675 ± 51.3%	239 ± 50.7%	1537 ± 51.0%
Sex: Male	332 ± 50.0%	272 ± 48.3%	640 ± 48.7%	232 ± 49.3%	1476 ± 49.0%